HUTCHMED (00013) will release clinical data at the 2025 European Society for Medical Oncology (ESMO) Asian Conference and the 2025 American Society of Hematology (ASH) Annual Meeting.

HUTCHMED (00013) announced that the latest and updated data from several studies of compounds developed independently by HUTCHMED will be presented at the European Society for Medical Oncology (ESMO) Asia Conference in Singapore from December 5 to 7, 2025, as well as at the American Society of Hematology (ASH) Annual Meeting in Orlando, USA from December 6 to 9, 2025. The results of the first human clinical trial of the anti-CD47 monoclonal antibody HMPL-A83 for the treatment of advanced solid tumors, as well as the results of the Phase II part of the FRUSICA-2 registration study of fruquintinib in combination with sintilimab for the second-line treatment of locally advanced or metastatic renal cell carcinoma, will be presented at the 2025 ESMO Asia Conference. In addition, the results of the Phase II part of the II/III study of surufatinib in combination with camrelizumab and chemotherapy for the first-line treatment of metastatic pancreatic cancer will also be presented at the conference.